메뉴 건너뛰기
American Family Physician
Volumn 85, Issue 9, 2012, Pages 910-911
Tapentadol (Nucynta) for treatment of pain
Author keywords

[No Author keywords available]
Indexed keywords

ALCOHOL; HYDROMORPHONE; MONOAMINE OXIDASE INHIBITOR; OXYCODONE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TAPENTADOL;
EID: 84860735266     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (6)
References (10)
  • 1
    • 85031182935 scopus 로고    scopus 로고
    • Highlights of prescribing information
    • Accessed January 5, 2011
    • Highlights of prescribing information. Nucynta (tapentadol) immediate-release oral tablets. http://www.nucynta.com/sites/all/themes/nucynta/pdf/Nucynta-PI.pdf. Accessed January 5, 2011.
    • Nucynta (tapentadol) immediate-release oral tablets
  • 3
    • 62149094353 scopus 로고    scopus 로고
    • Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active-and placebo-controlled study
    • Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active-and placebo-controlled study. Clin Ther. 2009;31(2):260-271.
    • (2009) Clin Ther. , vol.31 , Issue.2 , pp. 260-271
    • Hartrick, C.1    Van Hove, I.2    Stegmann, J.U.3    Oh, C.4    Upmalis, D.5
  • 4
    • 67649414317 scopus 로고    scopus 로고
    • Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double-blind study
    • Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009;25(5):1095-1104.
    • (2009) Curr Med Res Opin. , vol.25 , Issue.5 , pp. 1095-1104
    • Hale, M.1    Upmalis, D.2    Okamoto, A.3    Lange, C.4    Rauschkolb, C.5
  • 5
    • 67649435616 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain
    • [published correction appears in Curr Med Res Opin. 2009;25(6):1561]
    • Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain [published correction appears in Curr Med Res Opin. 2009;25(6):1561]. Curr Med Res Opin. 2009;25(6):1551-1561.
    • (2009) Curr Med Res Opin. , vol.25 , Issue.6 , pp. 1551-1561
    • Daniels, S.1    Casson, E.2    Stegmann, J.U.3
  • 6
    • 79958201835 scopus 로고    scopus 로고
    • Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride
    • Etropolski M, Kelly K, Okamoto A, Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011;28(5):401-417.
    • (2011) Adv Ther. , vol.28 , Issue.5 , pp. 401-417
    • Etropolski, M.1    Kelly, K.2    Okamoto, A.3    Rauschkolb, C.4
  • 7
    • 77954810443 scopus 로고    scopus 로고
    • Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain
    • Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10(5):416-427.
    • (2010) Pain Pract. , vol.10 , Issue.5 , pp. 416-427
    • Wild, J.E.1    Grond, S.2    Kuperwasser, B.3
  • 8
    • 85031192654 scopus 로고    scopus 로고
    • Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration., December. Accessed February 22, 2012
    • Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration. Tapentadol scheduling review document: eight factor analysis, December 2008. http://www.regulations.gov/#!documentDetail;D=DEA-2009-0002-0003. Accessed February 22, 2012.
    • (2008) Tapentadol scheduling review document: Eight factor analysis
  • 9
    • 78650394491 scopus 로고    scopus 로고
    • Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial
    • Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151-162.
    • (2011) Curr Med Res Opin. , vol.27 , Issue.1 , pp. 151-162
    • Schwartz, S.1    Etropolski, M.2    Shapiro, D.Y.3
  • 10
    • 85031180030 scopus 로고    scopus 로고
    • Drugstore.com Accessed February 14, 2012
    • Drugstore. com. http://www.drugstore.com. Accessed February 14, 2012.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.